Current ebola vaccines

Bibliography

• Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and ebola viruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. 5th edition. Lippincott Williams & Wilkins, Philadelphia; 2007. p. 1410-48
   Google Scholar
• Towner JS, Sealy TK, Khristova ML, Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212
   PubMed Web of Science ®Google Scholar
• WHO. WHO experts consultation on Ebola Reston pathogenicity in humans. 2009
   Google Scholar
• Barrette RW, Metwally SA, Rowland JM, Discovery of swine as a host for the Reston ebolavirus. Science 2009;325(5937):204-6
   PubMed Web of Science ®Google Scholar
• Beniac DR, Melito PL, Devarennes SL, The organisation of ebola virus reveals a capacity for extensive, modular polyploidy. PloS One 2012;7(1):e29608
   PubMed Web of Science ®Google Scholar
• Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377(9768):849-62
   PubMed Web of Science ®Google Scholar
• Hoenen T, Gottschalk R, Becker S. Ebolavirus hemmorrhagic fever. In: F. Hofmann, editor. Manual of Infectious Diseases. ecomed Medizin, Landsberg/Lech; 2007. VIII-6.11.1-15
   Google Scholar
• Baize S, Leroy EM, Georges-Courbot MC, Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5(4):423-6
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Rollin PE, Williams AJ, Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179(Suppl 1):S177-87
   PubMed Web of Science ®Google Scholar
• Sanchez A, Lukwiya M, Bausch D, Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004;78(19):10370-7
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Jahrling PB, Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003;362(9400):1953-8
   PubMed Web of Science ®Google Scholar
• Hensley LE, Stevens EL, Yan SB, Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S390-9
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Lee AC, Robbins M, Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375(9729):1896-905
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012;109(13):5034-9
   PubMed Web of Science ®Google Scholar
• Jeffs B. A clinical guide to viral haemorrhagic fevers: ebola, Marburg and Lassa. Trop Doct 2006;36(1):1-4
   PubMed Web of Science ®Google Scholar
• Nkoghe D, Formenty P, Nnegue S, Practical guidelines for the management of Ebola infected patients in the field. Med Trop 2004;64(2):199-204
   PubMedGoogle Scholar
• Leroy EM, Kumulungui B, Pourrut X, Fruit bats as reservoirs of Ebola virus. Nature 2005;438(7068):575-6
   PubMed Web of Science ®Google Scholar
• Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. Trends Microbiol 2007;15(9):408-16
   PubMed Web of Science ®Google Scholar
• Bermejo M, Rodriguez-Teijeiro JD, Illera G, Ebola outbreak killed 5000 gorillas. Science 2006;314(5805):1564
   PubMed Web of Science ®Google Scholar
• Leroy EM, Rouquet P, Formenty P, Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004;303(5656):387-90
   PubMed Web of Science ®Google Scholar
• Leroy EM, Epelboin A, Mondonge V, Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009;9(6):723-8
   PubMed Web of Science ®Google Scholar
• Taniguchi S, Watanabe S, Masangkay JS, Reston ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis 2011;17(8):1559-60
   PubMed Web of Science ®Google Scholar
• Marsh GA, Haining J, Robinson R, Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 2011;204(Suppl 3):S804-9
   PubMedGoogle Scholar
• Pratt WD, Wang D, Nichols DK, Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17(4):572-81
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999;179(Suppl 1):S248-58
   PubMed Web of Science ®Google Scholar
• Ebihara H, Takada A, Kobasa D, Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006;2(7):e73
   PubMed Web of Science ®Google Scholar
• Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001;82(Pt 6):1365-73
   PubMed Web of Science ®Google Scholar
• Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011;204(Suppl 3):S986-90
   PubMed Web of Science ®Google Scholar
• Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001;125(4):243-53
   PubMed Web of Science ®Google Scholar
• Ryabchikova E, Kolesnikova L, Smolina M, Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol 1996;141(5):909-21
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999;179(Suppl 1):S203-17
   PubMed Web of Science ®Google Scholar
• Ebihara H, Zivcec M, Gardner D, A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2012; In press
   PubMed Web of Science ®Google Scholar
• Baskerville A, Bowen ET, Platt GS, The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978;125(3):131-8
   PubMed Web of Science ®Google Scholar
• Bowen ET, Platt GS, Simpson DI, Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg 1978;72(2):188-91
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009;7(5):393-400
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17(9):1128-31
   PubMed Web of Science ®Google Scholar
• Lupton HW, Lambert RD, Bumgardner DL, Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet 1980;2(8207):1294-5
   PubMed Web of Science ®Google Scholar
• Rao M, Bray M, Alving CR, Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002;76(18):9176-85
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8(5):503-7
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000;19(1):142-53
   PubMed Web of Science ®Google Scholar
• Reynard O, Mokhonov V, Mokhonova E, Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3):S1060-5
   PubMedGoogle Scholar
• Vanderzanden L, Bray M, Fuller D, DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246(1):134-44
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J, Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003;21(25-26):4071-80
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408(6812):605-9
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13(11):1267-77
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424(6949):681-4
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006;3(6):e177
   PubMed Web of Science ®Google Scholar
• Richardson JS, Yao MK, Tran KN, Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PloS One 2009;4(4):e5308
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010;6(5):e1000904
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29(2):304-13
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28(4):950-7
   PubMed Web of Science ®Google Scholar
• Choi JH, Schafer SC, Zhang L, A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs. Mol Pharm 2012;9(1):156-67
   PubMed Web of Science ®Google Scholar
• Richardson JS, Abou MC, Tran KN, Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis 2011;204(Suppl 3):S1032-42
   PubMed Web of Science ®Google Scholar
• Croyle MA, Patel A, Tran KN, Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PloS One 2008;3(10):e3548
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006;346(2):394-401
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85(9):4222-33
   PubMed Web of Science ®Google Scholar
• Roy S, Zhi Y, Kobinger GP, Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol 2006;87(Pt 9):2477-85
   PubMed Web of Science ®Google Scholar
• Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003;92(2):187-93
   PubMed Web of Science ®Google Scholar
• Konduru K, Bradfute SB, Jacques J, Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 2011;29(16):2968-77
   PubMed Web of Science ®Google Scholar
• Phoolcharoen W, Dye JM, Kilbourne J, A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci USA 2011;108(51):20695-700
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005;23(23):3033-42
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bosio CM, Welcher BC, Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003;100(26):15889-94
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007;196(Suppl 2):S430-7
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL, Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007;196(Suppl 2):S421-9
   PubMed Web of Science ®Google Scholar
• Sun Y, Carrion R Jr, Ye L, Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009;383(1):12-21
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, de Kok-Mercado F, Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res 2011;91(2):195-208
   PubMed Web of Science ®Google Scholar
• Halfmann P, Kim JH, Ebihara H, Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA 2008;105(4):1129-33
   PubMed Web of Science ®Google Scholar
• Halfmann P, Ebihara H, Marzi A, Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009;83(8):3810-15
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11(7):786-90
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S404-12
   PubMedGoogle Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM, Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3(1):e2
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006;80(19):9659-66
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008;26(52):6894-900
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008;4(11):e1000225
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009;83(14):7296-304
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PloS One 2009;4(5):e5547
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008;82(11):5664-8
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Geisbert JB, Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010;16(7):1119-22
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Stroher U, Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006;367(9520):1399-404
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jones S, Fritz EA, Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005;2(6):e183
   PubMed Web of Science ®Google Scholar
• Falzarano D, Feldmann F, Grolla A, Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 2011;204(Suppl 3):S1082-9
   PubMedGoogle Scholar
• Mire CE, Miller AD, Carville A, Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012;6(3):e1567
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Safronetz D, Brown K, Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3):S1090-7
   PubMedGoogle Scholar
• Gunther S, Feldmann H, Geisbert TW, Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011;204(Suppl 3):S785-90
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Zaki SR, A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006;80(5):2267-79
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81(12):6379-88
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Marzi A, Feldmann F, Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009;383(2):348-61
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 2010;399(2):290-8
   PubMed Web of Science ®Google Scholar
• Blaney JE, Wirblich C, Papaneri AB, Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011;85(20):10605-16
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Caposio P, Parkins CJ, A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011;5(8):e1275
   PubMed Web of Science ®Google Scholar
• Marzi A, Ebihara H, Callison J, Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 2011;204(Suppl 3):S1066-74
   PubMed Web of Science ®Google Scholar